{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00554983",
      "orgStudyIdInfo": {
        "id": "AL0702rB"
      },
      "secondaryIdInfos": [
        {
          "id": "2007-001029-84",
          "type": "EUDRACT_NUMBER"
        }
      ],
      "organization": {
        "fullName": "Allergopharma GmbH & Co. KG",
        "class": "INDUSTRY"
      },
      "briefTitle": "Efficacy and Safety From a Recombinant Folding Variant of Bet v 1",
      "officialTitle": "A Multicentre Randomised Placebo-controlled Double-blind Pivotal Clinical Trial for the Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v 1-FV"
    },
    "statusModule": {
      "statusVerifiedDate": "2013-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2007-09"
      },
      "primaryCompletionDateStruct": {
        "date": "2010-06",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2012-05",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2007-11-06",
      "studyFirstSubmitQcDate": "2007-11-06",
      "studyFirstPostDateStruct": {
        "date": "2007-11-07",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2013-11-07",
      "lastUpdatePostDateStruct": {
        "date": "2013-11-08",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Allergopharma GmbH & Co. KG",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "Efficacy and Safety from a recombinant folding variant of Bet v 1"
    },
    "conditionsModule": {
      "conditions": [
        "Allergy"
      ],
      "keywords": [
        "Recombinant birch pollen allergy",
        "IgE-mediated allergic disease attributed to birch pollen"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 255,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "2",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Biological: placebo"
          ]
        },
        {
          "label": "1",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: recombinant birch pollen allergen"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "recombinant birch pollen allergen",
          "description": "subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram",
          "armGroupLabels": [
            "1"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "placebo",
          "description": "subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram",
          "armGroupLabels": [
            "2"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Symptom-Medication-Score",
          "timeFrame": "during pollen season"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Allergic rhinoconjunctivitis attributable to birch pollen\n* Positive SPT\n* Positive EAST\n* Positive specific provocation test\n\nExclusion Criteria:\n\n* Serious chronic diseases\n* Other perennial allergies",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "60 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ludger Klimek, Professor",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Allergopharma GmbH & Co. KG",
          "city": "Reinbek",
          "zip": "21465",
          "country": "Germany",
          "geoPoint": {
            "lat": 53.51703,
            "lon": 10.2488
          }
        }
      ]
    },
    "referencesModule": {
      "seeAlsoLinks": [
        {
          "label": "Leader in specific allergy research and therapy",
          "url": "http://www.allergopharma.de"
        },
        {
          "label": "Click here for information about this trial in the European Clinical Trials Register",
          "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001029-84/DE"
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        }
      ],
      "ancestors": [
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}